Jeff Schwaneke
In connection with his appointment, Mr. Schwaneke will resign from the agilon health, inc. Board of Directors.
Highest-materiality recent filing
agilon health Q2 net income $18M vs loss; raises FY2026 guidance
Total revenue $1.49B (+7% YoY); net income $18M vs net loss $104M in Q2 2025.
Q1 net income $49M vs $12M YoY; Adjusted EBITDA $54M vs $21M; medical margin $149M vs $128M.
agilon health appoints Tim O'Rourke as CEO, effective May 7, 2026
Tim O'Rourke appointed CEO/President, effective May 7, 2026; joins Board as Class III director.
agilon health to effect 1-for-25 reverse stock split on March 30, 2026 to maintain NYSE listing
Stockholders approved reverse split at special meeting on March 17; votes were 356,574,789 for, 6,187,388 against, 365,864 abstained.
agilon health Q4 net loss $189M, revenue $1.57B; 2026 guidance Adj EBITDA breakeven
Q4 net loss $189M vs $106M loss YoY; FY net loss $391M vs $260M loss.
agilon health amends credit agreement, extends maturity to 2028, reduces revolver to $90M
Maturity extended from Feb 2026 to Feb 2028 for $90M revolver (down from $100M).
agilon health receives NYSE delisting notice; plans reverse stock split
NYSE notified agilon on Nov 5, 2025 that avg closing price was below $1.00 over 30 trading days ended Nov 4, 2025.
agilon health Q3 net loss $110M; re-establishes FY2025 guidance with negative EBITDA outlook
Q3 2025 revenue $1.44B, down 1% YoY; net loss $110M vs $118M loss in Q3 2024.
CEO Sell resigns; agilon posts $104M Q2 net loss, suspends 2025 guidance
Steven Sell resigned as CEO/President and Board director effective July 29; Board reduced to seven directors.
agilon health Q1 2025 revenue $1.53B, net income $12M; reaffirms FY 2025 guidance
Total revenue $1.53B (down 4% YoY); Medicare Advantage members 491,000 (down 6%).
Q4 revenue $1.52B (+44% YoY); full-year revenue $6.06B (+40%). Medicare Advantage members 527,000 (+36%).
Medicare Advantage members grew 37% to 525,000; total platform members 657,000 (+39% YoY).
agilon health Q2 revenue up 39% to $1.48B but net loss widens to $31M
Revenue $1.48B (+39% YoY); MA membership 513K (+38%).
agilon health appoints Jeff Schwaneke as CFO, replacing retiring Tim Bensley effective July 1, 2024
Jeff Schwaneke, former Centene CFO (2016-2021) and EVP Health Care Enterprises, named CFO and EVP effective July 1, 2024.
agilon health Q1 revenue up 52% to $1.6B, net loss $6M; lowers FY2024 member & revenue guidance
Revenue $1.60B (+52% YoY); net loss of $6M vs net income $16M in Q1 2023.
Agilon health Q4 net loss $230M, medical margin negative $102M; FY2024 guidance slashed
Q4 revenue $1.06B (+72% YoY) but gross profit of negative $95M vs $16M a year ago.
Benjamin Kornitzer, M.D., transitions from CMO to special advisor effective March 1, 2024.
agilon health cuts 2023 medical margin guidance by ~$110M; withdraws 2026 outlook
2023 medical margin guidance lowered to $340M-$360M from $455M-$470M, a ~$110M reduction.
Net loss $31M (unchanged YoY); Adj. EBITDA loss $6M vs. $26M loss last year.
Revenue $1.15B, +71% YoY; Medicare Advantage members 408,900 (+57%); total members live on platform 495,900.
agilon health selling stockholders to sell 86.9M shares; company to repurchase 9.6M shares
Selling stockholders including CD&R Vector Holdings sell 86,884,353 shares of common stock.
agilon health Q1 revenue surges 74% to $1.14B; net income hits $16M
Revenue $1.14B (up 74% YoY); gross profit $77M vs $42M in Q1 2022.
Q4 revenue $690M (+49% YoY); FY2022 revenue $2.71B (+48%). Medicare Advantage members 269,500 (+45%).
agilon health raises 2023 MA membership outlook; guides 2023 Adj. EBITDA $75M-$90M
Reaffirmed 2022 Adjusted EBITDA guidance of $2M to $7M.
agilon health Q3 revenue +52% to $695M, medical margin up 74%, raises FY2022 guidance
Revenue $695M (+52% YoY); total platform members 356,000 with 266,600 MA members (+45%).
agilon health Q2 revenue up 34% to $670M, adjusted EBITDA turns positive at $7M
Revenue $670M (+34% YoY); normalized growth 42% excluding prior-year retroactive contract.
agilon health Q1 revenue up 58% to $653M, net income $1M, guides FY2022 revenue $2.5-2.6B
Revenue $653M (+58% YoY); normalized revenue growth 49%. Net income $1M vs $15M loss.
Q4 revenue $463M (+44% YoY); FY2021 revenue $1.83B (+50%).
In connection with his appointment, Mr. Schwaneke will resign from the agilon health, inc. Board of Directors.
On June 4, 2024, agilon health, inc. (the “Company”) appointed Jeff Schwaneke to serve as the Company’s Chief Financial Officer and Executive Vice President effective July 1, 2024 (the “Effective Date”).
Until a successor is named, Dr. Karthik Rao, senior medical director and vice president, network performance, will serve as interim CMO.
Effective March 1, 2024, Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to agilon health and will transition from his role as chief medical officer (CMO).
Timothy Bensley has informed agilon health, inc. (the “Company”) of his intent to retire from his position as Chief Financial Officer (CFO) of the Company during 2024, which the Company expects to take place within the next nine months.
Ms. Kasenchak will be succeeded by Timothy Gertsch, agilon heath’s Vice President, Controller, who assumed the role of Chief Accounting Officer on August 16, 2023.
On August 11, 2023, Priscilla Kasenchak, Chief Accounting Officer of agilon health, inc. (“agilon health”), notified agilon health of her decision to resign to pursue another professional opportunity.
On June 21, 2023, each of Richard Schnall, Clay Richards and Derek L. Strum tendered letters of resignation from the Board of Directors (the “Board”) of agilon health, inc. (the “Company”), which resignations were effective on June 22, 2023.
On June 21, 2023, each of Richard Schnall, Clay Richards and Derek L. Strum tendered letters of resignation from the Board of Directors (the “Board”) of agilon health, inc. (the “Company”), which resignations were effective on June 22, 2023.
On June 22, 2023, the Board, upon the recommendation of the Nominating and Governance Committee, appointed Silvana Battaglia as an independent Class I Director in accordance with the Company’s Amended and Restated Certificate of Incorporation, to fill the vacancy on the Board created by Mr. Richard’s resignation from the Board.
On June 21, 2023, each of Richard Schnall, Clay Richards and Derek L. Strum tendered letters of resignation from the Board of Directors (the “Board”) of agilon health, inc. (the “Company”), which resignations were effective on June 22, 2023.
Effective February 17, 2023, to fill a vacancy on the Board of Directors, Diana L. McKenzie was appointed to the Board as a Class II director in accordance with the Amended and Restated Certificate of Incorporation of agilon health, inc.
Max materiality 0.90 · Median 0.65 · Most common event earnings